Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

著者: Pasi A. Jänne, Alice T. Shaw, José Rodrigues Pereira, G. Jeannin, Johan Vansteenkiste, Carlos H. Barrios, Fábio Franke, Lynda Grinsted, Victoria Zazulina, Paul D. Smith, Ian C. P. Smith, Lucio Crinò - The Lancet 2012 被引用: 657